{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:26:36Z","timestamp":1780547196570,"version":"3.54.1"},"reference-count":96,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>With advancement in our understanding of pathogenic mechanisms in systemic lupus erythematosus (SLE), there is tremendous enthusiasm in examining drugs, old and new, to improve outcomes. This review highlights recent trials\u2019 successes and impasses that have come to fore.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Among B-cell therapies, belimumab continues its run of successes with sustained safety and tolerability documented in a long-term extension as well as the likely approval of a subcutaneous formulation in the near future. With greater antibody-dependent cytotoxicity and less immunogenicity, there is hope for obinituzumab to succeed where its anti-CD 20 predecessors have failed. Drugs targeting type I interferons \u2013 sifalimumab and anifrolumab \u2013 have been efficacious albeit with an increase in incidence of Herpes zoster infections. There is also renewed interest in evaluating the efficacy of calcineurin inhibitors, specifically tacrolimus in the induction and maintenance of lupus nephritis. Introspection into clinical trial designs have highlighted the effects of entry criteria, end points, background medications and geographical differences on study outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>There are at least 50 drugs and targets being evaluated in SLE. In addition to developing new drugs to treat lupus, future trials have to focus on more effective study designs to improve chances of trial success.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000311","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T12:43:09Z","timestamp":1466167389000},"page":"477-487","source":"Crossref","is-referenced-by-count":43,"title":["Update on clinical trials in systemic lupus erythematosus"],"prefix":"10.1097","volume":"28","author":[{"given":"Sonali","family":"Narain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/BOR.0000000000000205","article-title":"Advances in lupus genetics","volume":"27","author":"Niewold","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/08916930903374600","article-title":"Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future","volume":"43","author":"Jacob","year":"2010","journal-title":"Autoimmunity"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J Rheumatol"},{"issue":"(suppl 2)","key":"R8-20230828","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/annrheumdis-2015-eular.2326","article-title":"A randomized, open label study to evaluate the relative bioavailability of a single dose of belimumab administered subcutaneously by prefilled syringe or autoinjector","volume":"74","author":"Struemper","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 10)","key":"R9-20230828","article-title":"A randomized, double-blind, placebo-controlled, 52-week study of the efficacy and safety of belimumab administered subcutaneously plus standard care to patients with systemic lupus erythematosus (SLE)","volume":"67","author":"Stohl","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"e000118","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3899\/jrheum.150470","article-title":"Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices","volume":"42","author":"Hui-Yuen","year":"2015","journal-title":"J Rheumatol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall\u2019Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0961203309102803","article-title":"An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus","volume":"18","author":"Pena-Rossi","year":"2009","journal-title":"Lupus"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u2018peptibody\u2019 blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 10)","key":"R22-20230828","article-title":"The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized clinical trials","volume":"67","author":"Dooley","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20230828","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","article-title":"Obinutuzumab: a new class of anti-CD20 monoclonal antibody","volume":"26","author":"Gagez","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"(suppl 10)","key":"R29-20230828","article-title":"Obinutuzumab outperforms rituximab at inducing B-cell cytotoxicity in vitro through Fc-mediated effector mechanisms in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"(17\u201318)","key":"R30-20230828","first-page":"1413","article-title":"Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia\/lymphoma antibody, LL2","volume":"32","year":"1995","journal-title":"Mol Immunol"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2012-12-473744","article-title":"Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab","volume":"122","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/ket378","article-title":"Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006","volume":"53","author":"Strand","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"(S10)","key":"R36-20230828","first-page":"S885","article-title":"Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based Composite Lupus Assessment Endpoint","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"(suppl 10)","key":"R37-20230828","article-title":"Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized placebo-controlled trials","volume":"67","author":"Clowse","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"419029","DOI":"10.1155\/2014\/419029","article-title":"The pathology of T cells in systemic lupus erythematosus","volume":"2014","author":"Mak","year":"2014","journal-title":"J Immunol Res"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nrl.2010.07.027","article-title":"Oral laquinimod treatment in multiple sclerosis","volume":"26","author":"Fernandez","year":"2011","journal-title":"Neurologia"},{"issue":"(suppl 3)","key":"R41-20230828","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/annrheumdis-2013-eular.528","article-title":"A Randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care","volume":"72","author":"Jayne","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2009.03.009","article-title":"Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression","volume":"33","author":"Sthoeger","year":"2009","journal-title":"J Autoimmun"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/lupus-2015-000104","article-title":"Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study","volume":"2","author":"Urowitz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1002\/art.24027","article-title":"Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial","volume":"58","author":"Muller","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","article-title":"Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial","volume":"72","author":"Zimmer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0961203313511555","article-title":"Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A","volume":"23","author":"Zavada","year":"2014","journal-title":"Lupus"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11255-015-1201-z","article-title":"The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis","volume":"48","author":"Zhang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R54-20230828","article-title":"Administration of AMG 557, a human anti-B7RP-1 (ICOSL) antibody, leads to the selective inhibition of anti-KLH IgG responses in subjects with SLE: results of a phase 1 randomized, double-blind, placebo-controlled, sequential, rising, multiple-dose study","author":"Sullivan","year":"2013","journal-title":"ACR\/ARHP Annual Meeting"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02788753","article-title":"Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor","volume":"18","author":"Scheipers","year":"1998","journal-title":"Immunol Res"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with nonlife-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","article-title":"Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials","volume":"65","author":"Wofsy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study","volume":"66","author":"Group","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R62-20230828","first-page":"95","article-title":"Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus","volume":"28","author":"Davis","year":"2001","journal-title":"J Rheumatol"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/rheumatology\/kei118","article-title":"Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism","volume":"45","author":"Nakamura","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"(suppl 10)","key":"R65-20230828","article-title":"Repeated administration of dapirolizumab pegol (DZP) appears safe and well tolerated in patients with systemic lupus erythematosus (SLE) and is accompanied by an improvement in disease activity: results from a phase 1 study","volume":"67","author":"Chamberlain","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/cyto.2001.0934","article-title":"Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE","volume":"15","author":"Chuntharapai","year":"2001","journal-title":"Cytokine"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human antiinterferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human antiinterferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R74-20230828","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an antiinterferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 10)","key":"R75-20230828","article-title":"Functional and mechanistic characterization of anifrolumab, a fully human, anti-IFNAR1 monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"67","author":"Riggs","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R76-20230828","article-title":"Target modulation of a type I interferon (IFN) gene signature with sifalimumab or anifrolumab in systemic lupus erythematosus (SLE) patients in two open label phase 2 Japanese trials","author":"Morehouse","year":"2014","journal-title":"ACR\/ARHP Annual Meeting"},{"issue":"(suppl 10)","key":"R77-20230828","article-title":"Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE)","volume":"67","author":"Furie","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1073\/pnas.0900615106","article-title":"IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model","volume":"106","author":"Zagury","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/ard.2010.141101","article-title":"Active immunisation of human interferon alpha transgenic mice with a human interferon alpha Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus","volume":"70","author":"Mathian","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R81-20230828","article-title":"AMG 811 (anti-IFN-gamma) treatment leads to a reduction in the whole blood IFN-signature and serum CXCL10 in subjects with systemic lupus erythematosus: results of two phase I studies","author":"Martin","year":"2013","journal-title":"ACR\/ARHP Annual Meeting"},{"issue":"(suppl 2)","key":"R82-20230828","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/annrheumdis-2015-eular.2916","article-title":"A multiple dose study of AMG 811 (Anti IFN Gamma) in subjects with systemic lupus erythematosus and active nephritis","volume":"74","author":"Martin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R83-20230828","article-title":"Molecular, cellular and histopathologic assessment of baseline characteristics of sixteen subjects with discoid lupus erythematosus prior to treatment with AMG 811 (anti-IFN\u03b3)","author":"Sullivan","year":"2014","journal-title":"ACR\/ARHP Annual Meeting"},{"key":"R84-20230828","article-title":"A phase I single-dose crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus","author":"Werth","year":"2013","journal-title":"ACR\/ARHP Annual Meeting"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J Clin Immunol"},{"key":"R86-20230828","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R87-20230828","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"(suppl 2)","key":"R88-20230828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2014-eular.3974","article-title":"A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 2)","key":"R89-20230828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2015-eular.1428","article-title":"Significant clinical improvement and reduction of severe flares following administration of an IL-6 monoclonal antibody in systemic lupus erythematosus (SLE) subjects with high disease activity","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R90-20230828","article-title":"Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized systemic lupus erythematosus (SLE)","author":"Wallace","year":"2014","journal-title":"ACR\/ARHP Annual Meeting"},{"key":"R91-20230828","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R92-20230828","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"R93-20230828","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"R94-20230828","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral JAK1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"(suppl 2)","key":"R95-20230828","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/annrheumdis-2015-eular.3498","article-title":"The CRL4 cereblon on E3 ubiquitin ligase modulator CC-220 induces degeneration of the transcription factors Aiolos and Ikaros: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"74","author":"Schafer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 2)","key":"R96-20230828","first-page":"1075","article-title":"Safety and efficacy of low-dose interleukin-2 treatment in systemic lupus erythematosus","volume":"74","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201609000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:03:50Z","timestamp":1748988230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201609000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000311","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}